Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMAD R BOLOURI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1659322691
CMS profile
29086
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$3,758.34

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,402.00 2
Food and Beverage $356.34 13

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $3,570.98 4
Lilly USA, LLC $59.47 4
Corium, LLC $52.30 3
Avanir Pharmaceuticals, Inc. $38.70 2
Neurocrine Biosciences, Inc. $36.89 2

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMAD R BOLOURI

NPI 1659322691 · CMS profile ID 29086

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659322691?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659322691?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659322691?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1659322691?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $3,758.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $133.9511/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923408185 CMS
Lilly USA, LLC $14.5111/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918208419 CMS
Corium, LLC $19.6311/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924848117 CMS
Corium, LLC $17.1310/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924848115 CMS
Corium, LLC $15.5409/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924848113 CMS
Biogen, Inc. $35.0309/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923441481 CMS
Neurocrine Biosciences, Inc. $15.5909/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963438095 CMS
Lilly USA, LLC $13.7808/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918207629 CMS
Neurocrine Biosciences, Inc. $21.3008/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963437973 CMS
Avanir Pharmaceuticals, Inc. $18.9906/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935954437 CMS
Lilly USA, LLC $16.0706/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918232285 CMS
Avanir Pharmaceuticals, Inc. $19.7104/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935943953 CMS
Lilly USA, LLC $15.1103/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918186379 CMS
Biogen, Inc. $1,134.0003/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923393425 CMS
Biogen, Inc. $2,268.0001/03/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923397391 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,343.30 32
PY2020 $733.57 2
PY2021 $39.36 2
PY2022 $3,758.34 15
PY2023 $10,255.80 39
PY2024 $25,153.09 51
PY2025 $8,393.72 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,948,171.02 223
PY2024 Recipient $42,149.90 1
PY2024 Principal investigator $2,006,224.93 95
PY2023 Recipient $150.00 1
PY2023 Principal investigator $3,166,315.18 100
PY2022 Recipient $250.00 1
PY2022 Principal investigator $2,451,442.73 165
PY2021 Principal investigator $2,459,911.12 123
PY2020 Recipient $1,077.94 1
PY2020 Principal investigator $1,535,993.16 168
PY2019 Principal investigator $1,981,815.06 222

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

169 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $2,856.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131767
Principal investigator 1 Eisai Inc. $2,904.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131769
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131771
Principal investigator 1 Eisai Inc. $2,856.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131773
Principal investigator 1 Eisai Inc. $2,904.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131775
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131777
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131779
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131781
Principal investigator 1 Eisai Inc. $1,442.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131787
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131789
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131791
Principal investigator 1 Eisai Inc. $1,481.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131793
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131795
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131797
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131799
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131801
Principal investigator 1 Eisai Inc. $1,591.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131803
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131805
Principal investigator 1 Eisai Inc. $1,442.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131819
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131821
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131823
Principal investigator 1 Eisai Inc. $1,738.10 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131825
Principal investigator 1 Eisai Inc. $1,738.10 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131827
Principal investigator 1 Eisai Inc. $1,387.00 12/29/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131829
Principal investigator 1 Eisai Inc. $2,904.00 12/22/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131763
Principal investigator 1 Eisai Inc. $150.00 12/22/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131765
Principal investigator 1 Eisai Inc. $56,188.80 12/21/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749132107
Principal investigator 1 Genentech, Inc. $7,000.00 12/21/2020 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB OPEN LABEL EXTENSION No dispute reported 06/30/2026 857142181
Principal investigator 1 Eisai Inc. $2,904.00 12/10/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131751
Principal investigator 1 Eisai Inc. $50.00 12/10/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131753
Principal investigator 1 Eisai Inc. $45,757.80 12/08/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749132257
Principal investigator 1 Genentech, Inc. $5,090.00 11/20/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 857142171
Principal investigator 1 Genentech, Inc. $42,533.00 11/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 857142175
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131013
Principal investigator 1 Eisai Inc. $1,442.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131015
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131017
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131019
Principal investigator 1 Eisai Inc. $1,442.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131021
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131023
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131025
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131027
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131029
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131031
Principal investigator 1 Eisai Inc. $2,904.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131033
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131125
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131127
Principal investigator 1 Eisai Inc. $1,442.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131129
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131131
Principal investigator 1 Eisai Inc. $2,856.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131133
Principal investigator 1 Eisai Inc. $1,387.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131135
Principal investigator 1 Eisai Inc. $1,442.00 10/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131137
Principal investigator 1 Eisai Inc. $47,601.00 10/15/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749132017
Principal investigator 1 Eli Lilly and Company $277.00 09/24/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A STUDY OF HEALTH CARE USE AND COSTS IN PARTICIPANTS WITH EARLY STAGE ALZHEIMER'S DISEASE AD GERAS US No dispute reported 06/30/2026 728731551
Principal investigator 1 Eisai Inc. $27,007.20 09/21/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749132235
Principal investigator 1 Genentech, Inc. $10,851.00 09/17/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 743028827
Principal investigator 1 Eisai Inc. $1,442.00 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131105
Principal investigator 1 Eisai Inc. $1,387.00 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131107
Principal investigator 1 Eisai Inc. $1,387.00 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131109
Principal investigator 1 Eisai Inc. $1,387.00 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131111
Principal investigator 1 Eisai Inc. $1,481.00 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131289
Principal investigator 1 Eisai Inc. $1,387.00 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131291
Principal investigator 1 Eisai Inc. $1,387.00 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131293
Principal investigator 1 Eisai Inc. $1,481.00 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131295
Principal investigator 1 Eisai Inc. $1,442.00 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131297
Principal investigator 1 Eisai Inc. $1,387.00 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131299
Principal investigator 1 Eisai Inc. $424.35 09/01/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131689
Principal investigator 1 Genentech, Inc. $84,614.00 09/01/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 743028820
Principal investigator 1 Eisai Inc. $52,817.40 08/19/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749132005
Principal investigator 1 Genentech, Inc. $5,000.00 08/19/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 743028813
Principal investigator 1 Eisai Inc. $2,957.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131091
Principal investigator 1 Eisai Inc. $2,904.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131093
Principal investigator 1 Eisai Inc. $1,387.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131095
Principal investigator 1 Eisai Inc. $1,387.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131097
Principal investigator 1 Eisai Inc. $1,481.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131099
Principal investigator 1 Eisai Inc. $1,387.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131101
Principal investigator 1 Eisai Inc. $1,387.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131103
Principal investigator 1 Eisai Inc. $2,957.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131139
Principal investigator 1 Eisai Inc. $2,904.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131141
Principal investigator 1 Eisai Inc. $1,387.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131145
Principal investigator 1 Eisai Inc. $1,387.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131147
Principal investigator 1 Eisai Inc. $1,387.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131149
Principal investigator 1 Eisai Inc. $1,442.00 07/31/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131151
Principal investigator 1 Eisai Inc. $25,351.70 07/21/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749130999
Principal investigator 1 Eisai Inc. $75.00 07/16/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749131089
Principal investigator 1 Eisai Inc. $26,222.60 07/16/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131275
Principal investigator 1 Eisai Inc. $6,894.60 07/08/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 749126317
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,632.00 07/08/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY OF TWO DOSES OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF AD No dispute reported 06/30/2026 721489265
Principal investigator 1 Eisai Inc. $4,595.00 06/24/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 749126251
Principal investigator 1 Eisai Inc. $1,917.00 06/24/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 749126307
Principal investigator 1 Eisai Inc. $660.00 06/24/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 749126309
Principal investigator 1 Eisai Inc. $72,662.40 06/19/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131357
Principal investigator 1 Eisai Inc. $129,478.50 06/19/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131635
Recipient Eli Lilly and Company $1,077.94 06/04/2020 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 728723591
Principal investigator 1 Eisai Inc. $2,013.00 06/03/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 749126275
Principal investigator 1 Genentech, Inc. $46,387.00 06/03/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 743028805
Principal investigator 1 Genentech, Inc. $6,353.00 06/01/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 743028797
Principal investigator 1 Genentech, Inc. $2,740.00 05/25/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 743028791
Principal investigator 1 Eisai Inc. $2,582.00 05/22/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 749126245
Principal investigator 1 Eisai Inc. $639.00 05/22/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 749126247
Principal investigator 1 Eisai Inc. $1,500.00 05/15/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 749126253
Principal investigator 1 Eisai Inc. $1,387.00 05/12/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130755
Principal investigator 1 Eisai Inc. $1,387.00 05/12/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130767
Principal investigator 1 Eisai Inc. $1,442.00 05/12/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130769
Principal investigator 1 Eisai Inc. $1,387.00 05/12/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130771
Principal investigator 1 Eisai Inc. $1,387.00 05/12/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130773
Principal investigator 1 Eisai Inc. $2,957.00 05/12/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130775
Principal investigator 1 Eisai Inc. $2,904.00 05/12/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130777
Principal investigator 1 Eisai Inc. $1,387.00 05/12/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130779
Principal investigator 1 Eisai Inc. $1,500.00 05/05/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131085
Principal investigator 1 Eisai Inc. $1,500.00 05/05/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131087
Principal investigator 1 Biogen, Inc. $303,722.68 04/23/2020 Non-covered Recipient Entity
AMC Research, LLC
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 736755091
Principal investigator 1 Eli Lilly and Company $8,880.00 04/15/2020 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
A STUDY OF HEALTH CARE USE AND COSTS IN PARTICIPANTS WITH EARLY STAGE ALZHEIMER'S DISEASE AD GERAS US No dispute reported 06/30/2026 728729669
Principal investigator 1 Genentech, Inc. $14,032.00 04/13/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 743028779
Principal investigator 1 Eisai Inc. $838.50 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749130657
Principal investigator 1 Eisai Inc. $560.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749130659
Principal investigator 1 Eisai Inc. $360.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749130661
Principal investigator 1 Eisai Inc. $1,591.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130683
Principal investigator 1 Eisai Inc. $1,387.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130685
Principal investigator 1 Eisai Inc. $1,387.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130687
Principal investigator 1 Eisai Inc. $1,387.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130689
Principal investigator 1 Eisai Inc. $1,387.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130691
Principal investigator 1 Eisai Inc. $1,387.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130693
Principal investigator 1 Eisai Inc. $1,442.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130695
Principal investigator 1 Eisai Inc. $1,387.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130697
Principal investigator 1 Eisai Inc. $1,387.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130699
Principal investigator 1 Eisai Inc. $1,591.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130701
Principal investigator 1 Eisai Inc. $1,387.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130703
Principal investigator 1 Eisai Inc. $1,387.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130705
Principal investigator 1 Eisai Inc. $1,442.00 03/26/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130707
Principal investigator 1 Eisai Inc. $453.00 03/24/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749130671
Principal investigator 1 Eisai Inc. $422.00 03/24/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749130673
Principal investigator 1 Eisai Inc. $1,833.00 03/24/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749130675
Principal investigator 1 Eisai Inc. $1,833.00 03/24/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749130677
Principal investigator 1 Eisai Inc. $1,388.00 03/24/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749130679
Principal investigator 1 Eisai Inc. $1,615.00 03/24/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749130681
Principal investigator 1 Eisai Inc. $70,005.60 03/23/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131585
Principal investigator 1 Genentech, Inc. $63,105.00 03/16/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 743028773
Principal investigator 1 Eisai Inc. $41,427.90 03/06/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131811
Principal investigator 1 Eisai Inc. $1,186.00 02/27/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127661
Principal investigator 1 Eisai Inc. $1,186.00 02/27/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127663
Principal investigator 1 Eisai Inc. $1,186.00 02/27/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127665
Principal investigator 1 Eisai Inc. $1,186.00 02/27/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127667
Principal investigator 1 Eisai Inc. $1,186.00 02/27/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127669
Principal investigator 1 Eisai Inc. $5,000.00 02/25/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130633
Principal investigator 1 Eisai Inc. $1,500.00 02/25/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130653
Principal investigator 1 Eisai Inc. $50.00 02/25/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130655
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,805.83 02/10/2020 Non-covered Recipient Entity
ANI Neurology PLLC
PoCC dose finding in Mild to Moderate AD No dispute reported 06/30/2026 751191465
Principal investigator 1 Eisai Inc. $2,981.00 02/07/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127039
Principal investigator 1 Eisai Inc. $2,981.00 02/07/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127041
Principal investigator 1 Eisai Inc. $2,981.00 02/07/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127043
Principal investigator 1 Eisai Inc. $2,981.00 02/07/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127045
Principal investigator 1 Eisai Inc. $300.00 02/06/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127217
Principal investigator 1 Eisai Inc. $1,657.00 01/28/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749126365
Principal investigator 1 Eisai Inc. $1,615.00 01/28/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749126369
Principal investigator 1 Eisai Inc. $1,387.00 01/28/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126559
Principal investigator 1 Eisai Inc. $1,387.00 01/28/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126561
Principal investigator 1 Eisai Inc. $1,442.00 01/28/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126563
Principal investigator 1 Eisai Inc. $1,387.00 01/28/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126565
Principal investigator 1 Eisai Inc. $1,387.00 01/28/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126567
Principal investigator 1 Eisai Inc. $1,591.00 01/28/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126569
Principal investigator 1 Eisai Inc. $1,387.00 01/28/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126571
Principal investigator 1 Eisai Inc. $1,387.00 01/28/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126837
Principal investigator 1 Eisai Inc. $67,615.20 01/20/2020 Non-covered Recipient Entity
AMC RESEARCH LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749131575
Principal investigator 1 Avanir Pharmaceuticals, Inc. $250.00 01/09/2020 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
15-AVP-786-303 No dispute reported 06/30/2026 722219501
Principal investigator 1 Avanir Pharmaceuticals, Inc. $3,000.00 01/09/2020 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
15-AVP-786-302 No dispute reported 06/30/2026 722219503
Principal investigator 1 Genentech, Inc. $5,197.00 01/08/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 743028765
Principal investigator 1 Eisai Inc. $4,290.00 01/07/2020 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126825
Principal investigator 1 Biogen, Inc. $4,943.00 01/02/2020 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease No dispute reported 06/30/2026 736753817
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,361.90 01/01/2020 Non-covered Recipient Entity
ANI NEUROLOGY PLLC DBA ALZHEIMERS MEMORY CENTER
A 5 YEAR PROSPECTIVE STUDY OF AN ANTI AMYLOID THERAPY CAD106 OR CNP520 IN SLOWING AND OR POSTPONING COGNITIVE DECLINE IN ASYMPTOMATIC APOE 4 HOMOZYGOTES AT RISK FOR DEVELOPING ALZHEIMERS DISEASE DEMENTIA No dispute reported 06/30/2026 721489311